Martin C Michel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11328517/publications.pdf

Version: 2024-02-01

227 papers	11,682 citations	26630 56 h-index	37204 96 g-index
232 all docs	232 docs citations	232 times ranked	9736 citing authors

#	Article	IF	Citations
1	Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient Benefit. Biomedicines, 2022, 10, 270.	3.2	3
2	Does coupling to ADP ribosylation factor 6 explain differences between muscarinic and other receptors in interaction with Î²-adrenoceptor-mediated smooth muscle relaxation?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 381-386.	3.0	1
3	What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine. Advances in Therapy, 2022, 39, 2489-2501.	2.9	5
4	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 867-885.	3.0	12
5	Established and emerging treatments for diabetes-associated lower urinary tract dysfunction. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 887-906.	3.0	10
6	Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment. Neurourology and Urodynamics, 2022, 41, 1399-1405.	1.5	3
7	Modelâ€based metaâ€analysis of the time to first acute urinary retention or benign prostatic hyperplasiaâ€related surgery in patients with moderate or severe symptoms. British Journal of Clinical Pharmacology, 2021, 87, 2777-2789.	2.4	8
8	Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting. Journal of Clinical Medicine, 2021, 10, 311.	2.4	8
9	Medications and Drug Targets for the Treatment of Diseases of the Urinary Bladder and Urethra. , 2021, , .		0
10	Function and morphology of the urinary bladder after denervation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 320, R833-R834.	1.8	2
11	Effects of Nifedipine on Renal and Cardiovascular Responses to Neuropeptide Y in Anesthetized Rats. Molecules, 2021, 26, 4460.	3.8	1
12	Normalization of organ bath contraction data for tissue specimen size: does one approach fit all?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 243-251.	3.0	18
13	Expression and Signaling of Î²-Adrenoceptor Subtypes in the Diabetic Heart. Cells, 2020, 9, 2548.	4.1	6
14	A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes. Cells, 2020, 9, 1923.	4.1	14
15	Cardiac and Vascular Î±1-Adrenoceptors in Congestive Heart Failure: A Systematic Review. Cells, 2020, 9, 2412.	4.1	10
16	Î±1-adrenoceptor activity of Î²-adrenoceptor ligands â€“ An expected drug property with limited clinical relevance. European Journal of Pharmacology, 2020, 889, 173632.	3.5	12
17	New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 136-147.	2.5	53
18	Impact of guideline awareness in public pharmacies on counseling of patients with acute or chronic constipation in a survey of pharmacy personnel. BMC Gastroenterology, 2020, 20, 191.	2.0	3

#	Article	IF	Citations
19	Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study. Frontiers in Pharmacology, 2020, 11, 816.	3.5	8
20	Where will the next generation of medical treatments for overactive bladder syndrome come from?. International Journal of Urology, 2020, 27, 289-294.	1.0	15
21	Desensitization of cAMP Accumulation via Human Î²3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists. Frontiers in Pharmacology, 2019, 10, 596.	3.5	7
22	Cognitive and mood side effects of lower urinary tract medication. Expert Opinion on Drug Safety, 2019, 18, 915-923.	2.4	22
23	Why Are New Drugs Expensive and How Can They Stay Affordable?. Handbook of Experimental Pharmacology, 2019, 260, 453-466.	1.8	5
24	Agonistâ€induced desensitisation of Î²₃â€adrenoceptors: Where, when, and how?. British Journal of Pharmacology, 2019, 176, 2539-2558.	5.4	26
25	Î²₃â€Adrenoceptors in the normal and diseased urinary bladderâ€”What are the open questions?. British Journal of Pharmacology, 2019, 176, 2525-2538.	5.4	33
26	Cardiac Î²₃â€adrenoceptorsâ€”A role in human pathophysiology?. British Journal of Pharmacology, 2019, 176, 2482-2495.	5.4	21
27	Building Robustness into Translational Research. Handbook of Experimental Pharmacology, 2019, 257, 163-175.	1.8	7
28	Biased Agonism in Drug Discoveryâ€”Is It Too Soon to Choose a Path?. Molecular Pharmacology, 2018, 93, 259-265.	2.3	76
29	Lower Urinary Tract Symptoms: Whatâ€™s New in Medical Treatment?. European Urology Focus, 2018, 4, 17-24.	3.1	23
30	Commentary on the BJP's new statistical reporting guidelines. British Journal of Pharmacology, 2018, 175, 3636-3637.	5.4	10
31	A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences. Neurourology and Urodynamics, 2018, 37, 2346-2360.	1.5	28
32	Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 675-694.	3.0	32
33	Do Î²₃-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?. American Journal of Physiology - Renal Physiology, 2017, 313, F859-F861.	2.7	9
34	The Î²₃â€adrenoceptor agonist mirabegron increases human atrial force through Î²₁â€adrenoceptors: an indirect mechanism?. British Journal of Pharmacology, 2017, 174, 2706-2715.	5.4	43
35	Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customersÂwith common cold symptoms. International Journal of Clinical Practice, 2017, 71, e12907.	1.7	15
36	Pathophysiological Factors in the Relationship between Chronological Age and Calculated Lung Age as Detected in a Screening Setting in Community-Dwelling Subjects. Frontiers in Medicine, 2016, 3, 2.	2.6	3

#	Article	IF	Citations
37	Î²-Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in Î²2-Adrenoceptor Knockout Mice. Frontiers in Pharmacology, 2016, 7, 118.	3.5	6
38	Opportunities and Challenges for Drug Development: Publicâ€“Private Partnerships, Adaptive Designs and Big Data. Frontiers in Pharmacology, 2016, 7, 461.	3.5	60
39	Î²3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. , 2016, 159, 66-82.		52
40	Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. , 2016, 164, 1-81.		55
41	Editorial Comment. Journal of Urology, 2016, 196, 1808-1808.	0.4	1
42	Cellular basis of detrusor smooth muscle contraction. BJU International, 2016, 117, 177-178.	2.5	3
43	Impact of Formulation on the Pharmacokinetic Profile of Dutasteride. Clinical Drug Investigation, 2016, 36, 769-770.	2.2	0
44	Preclinical research strategies for newly approved drugs as reflected in early publication patterns. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 187-199.	3.0	4
45	Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 201-209.	3.0	4
46	Safety and tolerability of Î²₃-adrenoceptor agonists in the treatment of overactive bladder syndrome â€“ insight from transcriptosome and experimental studies. Expert Opinion on Drug Safety, 2016, 15, 647-657.	2.4	42
47	Use of Antibodies in the Research on Muscarinic Receptor Subtypes. Neuromethods, 2016, , 83-94.	0.3	2
48	Are blood vessels a target to treat lower urinary tract dysfunction?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 687-694.	3.0	22
49	How much potential for transient receptor potential channels in the bladder?. BJU International, 2015, 115, 350-351.	2.5	0
50	Therapeutic targets for overactive bladder other than smooth muscle. Expert Opinion on Therapeutic Targets, 2015, 19, 687-705.	3.4	20
51	Selectivity of pharmacological tools: implications for use in cell physiology. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms. American Journal of Physiology - Cell Physiology, 2015, 308, C505-C520.	4.6	20
52	Î²3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 749-759.	3.0	18
53	Regulation of GAPDH expression by treatment with the Î²-adrenoceptor agonist isoprenalineâ€”is GADPH a suitable loading control in immunoblot experiments?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1119-1120.	3.0	14
54	Therapeutic Modulation of Urinary Bladder Function: Multiple Targets at Multiple Levels. Annual Review of Pharmacology and Toxicology, 2015, 55, 269-287.	9.4	21

#	Article	IF	Citations
55	Rat Î²3-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 1117-1127.	3.0	17
56	Bradykinin Contracts Rat Urinary Bladder Largely Independently of Phospholipase C. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 25-31.	2.5	13
57	Longâ€term safety, tolerability and efficacy of flexibleâ€dose fesoterodine in elderly patients with overactive bladder: Openâ€label extension of the SOFIA trial. Neurourology and Urodynamics, 2014, 33, 106-114.	1.5	47
58	Muscarinic receptor subtype mRNA expression in the human prostate: association with age, pathological diagnosis, prostate size, or potentially interfering medications?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 207-214.	3.0	8
59	Do Î²-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 215-224.	3.0	30
60	The Î±_{1B}â€adrenoceptor subtype mediates adrenergic vasoconstriction in mouse retinal arterioles with damaged endothelium. British Journal of Pharmacology, 2014, 171, 3858-3867.	5.4	21
61	The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. Pharmacological Reviews, 2014, 66, 222-307.	16.0	418
62	Cardiovascular and ocular safety of Î±₁-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opinion on Drug Safety, 2014, 13, 1187-1197.	2.4	41
63	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 505-521.	3.0	97
64	The Odd Sibling: Features ofÎ²₃-Adrenoceptor Pharmacology. Molecular Pharmacology, 2014, 86, 479-484.	2.3	73
65	Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability. Neurourology and Urodynamics, 2014, 33, 17-30.	1.5	228
66	The pharmacological rationale for combining muscarinic receptor antagonists and Î²-adrenoceptor agonists in the treatment of airway and bladder disease. Current Opinion in Pharmacology, 2014, 16, 31-42.	3.5	45
67	Î²3-Adrenoceptors: a drug target in ophthalmology?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 265-267.	3.0	9
68	Agonist-induced desensitization of human Î²3-adrenoceptors expressed in human embryonic kidney cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 843-851.	3.0	16
69	A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists. Pharmacological Reviews, 2013, 65, 809-848.	16.0	233
70	Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 135-154.	3.0	34
71	The new radioligand [3H]-L 748,337 differentially labels human and rat Î²3-adrenoceptors. European Journal of Pharmacology, 2013, 720, 124-130.	3.5	23
72	Bradykinin modulates spontaneous nerve growth factor production and stretch-induced ATP release in human urothelium. Pharmacological Research, 2013, 70, 147-154.	7.1	25

#	Article	IF	Citations
73	Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases. Pharmacological Research, 2013, 74, 1-6.	7.1	24
74	Pharmacological profile of Î²3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 177-183.	3.0	71
75	EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. European Urology, 2013, 64, 118-140.	1.9	990
76	Are polymorphisms of the Î²₃â€adrenoceptor gene associated with an altered bladder function?. Neurourology and Urodynamics, 2013, 32, 276-280.	1.5	15
77	Flexibleâ€Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Doubleâ€Blind, Placeboâ€Controlled Study of Fesoterodine in an Aging Population Trial. Journal of the American Geriatrics Society, 2013, 61, 185-193.	2.6	95
78	Editorial Comment from <scp>D</scp>r <scp>M</scp>ichel to Expression and functional role of Î²₃â€adrenoceptors in the human ureter. International Journal of Urology, 2013, 20, 1015-1015.	1.0	0
79	Can you blame cold feet on Epac (and Rap1A)? Focus on â€œCyclic AMP-Rap1A signaling activates RhoA to induce Î±2C-adrenoceptor translocation to the cell surface of microvascular smooth muscle cellsâ€. American Journal of Physiology - Cell Physiology, 2012, 303, C488-C489.	4.6	6
80	Specificity evaluation of antibodies against human Î²3-adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 875-882.	3.0	35
81	A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Î²3-Adrenoceptor Agonist Solabegron for Overactive Bladder. European Urology, 2012, 62, 834-840.	1.9	96
82	A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Managementâ€”a Systematic Review and Meta-analysis. European Urology, 2012, 62, 877-890.	1.9	231
83	The Effect of Elective Sham Dose Escalation on the Placebo Response During an Antimuscarinic Trial for Overactive Bladder Symptoms. Journal of Urology, 2012, 187, 1721-1726.	0.4	6
84	A Comprehensive Review of the Pharmacodynamics, Pharmacokinetics, and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril. Frontiers in Pharmacology, 2012, 3, 93.	3.5	49
85	Functional investigation of Î²-adrenoceptors in human isolated detrusor focusing on the novel selective Î²3-adrenoceptor agonist KUC-7322. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 759-767.	3.0	28
86	Expression profiling of Gâ€proteinâ€coupled receptors in human urothelium and related cell lines. BJU International, 2012, 110, E293-300.	2.5	34
87	Transient receptor potential vanilloid 1 mediates nerve growth factorâ€induced bladder hyperactivity and noxious input. BJU International, 2012, 110, E422-8.	2.5	27
88	Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa. Pharmacological Research, 2011, 64, 420-425.	7.1	19
89	Î²-Adrenergic Receptor Subtypes in the Urinary Tract. Handbook of Experimental Pharmacology, 2011, , 307-318.	1.8	32
90	Understanding Dose Titration: Overactive Bladder Treatment With Fesoterodine as an Example. European Urology Supplements, 2011, 10, 8-13.	0.1	13

#	Article	IF	Citations
91	Human Urinary Bladder Strip Relaxation by the Î²-Adrenoceptor Agonist Isoprenaline: Methodological Considerations and Effects of Gender and Age. Frontiers in Pharmacology, 2011, 2, 11.	3.5	22
92	A comprehensive nonâ€clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. British Journal of Clinical Pharmacology, 2011, 72, 235-246.	2.4	152
93	Clinical pharmacology of functional disorders of the urogenital system. British Journal of Clinical Pharmacology, 2011, 72, 183-185.	2.4	1
94	Are there functional Î²₃â€adrenoceptors in the human heart?. British Journal of Pharmacology, 2011, 162, 817-822.	5.4	34
95	Î²-Adrenoceptor agonist effects in experimental models of bladder dysfunction. , 2011, 131, 40-49.		29
96	Lack of evidence that nebivolol is a Î²3-adrenoceptor agonist. European Journal of Pharmacology, 2011, 654, 86-91.	3.5	29
97	Desirable properties of Î²3-adrenoceptor agonists: Implications for the selection of drug development candidates. European Journal of Pharmacology, 2011, 657, 1-3.	3.5	10
98	The muscarinic receptor antagonist propiverine exhibits Î±1-adrenoceptor antagonism in human prostate and porcine trigonum. World Journal of Urology, 2011, 29, 149-155.	2.2	14
99	Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxation. Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 384, 555-563.	3.0	19
100	Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourology and Urodynamics, 2011, 30, 1227-1241.	1.5	115
101	Effects of voluntary dose escalation in a placeboâ€controlled, flexibleâ€dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics, 2011, 30, 1480-1485.	1.5	33
102	The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Î±-Blockers in the Treatment of Male Voiding Dysfunction â€" How Do They Work and Why Do They Differ in Tolerability?. Journal of Pharmacological Sciences, 2010, 112, 151-157.	2.5	39
103	Tissue functions mediated by Î²3-adrenoceptorsâ€"findings and challenges. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 382, 103-108.	3.0	39
104	Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations. Clinical Pharmacokinetics, 2010, 49, 177-188.	3.5	55
105	The Pharmacological Profile of the Î±1A-Adrenoceptor Antagonist Silodosin. European Urology Supplements, 2010, 9, 486-490.	0.1	14
106	Sphingosine-1-phosphate regulates RGS2 and RGS16 mRNA expression in vascular smooth muscle cells. European Journal of Pharmacology, 2009, 606, 25-31.	3.5	8
107	Basic Mechanisms of Urgency: Preclinical and Clinical Evidence. European Urology, 2009, 56, 298-308.	1.9	66
108	The effect of bladder outlet obstruction on Î±₁â€•and Î²â€adrenoceptor expression and function. Neurourology and Urodynamics, 2009, 28, 349-355.	1.5	42

#	Article	IF	Citations
109	Activation of sphingosine kinase by muscarinic receptors enhances NO-mediated and attenuates EDHF-mediated vasorelaxation. Basic Research in Cardiology, 2009, 104, 50-59.	5.9	28
110	Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 397-402.	3.0	131
111	How reliable are G-protein-coupled receptor antibodies?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 385-388.	3.0	264
112	Nocturia: A nonâ€specific but important symptom of urological disease. International Journal of Urology, 2009, 16, 249-256.	1.0	50
113	Do gene polymorphisms alone or in combination affect the function of human Î²₃â€adrenoceptors?. British Journal of Pharmacology, 2009, 156, 127-134.	5.4	41
114	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Current Opinion in Urology, 2009, 19, 380-394.	1.8	161
115	Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?. Current Opinion in Urology, 2009, 19, 13-19.	1.8	29
116	Pharmacotherapy of Urgency Incontinence. , 2009, , 191-201.		0
117	Pharmacotherapy of Urgency Incontinence. , 2009, , 191-201.		0
118	Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and Î²-adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 449-462.	3.0	139
119	Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 217-224.	3.0	18
120	Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.0	20
121	Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue. Pflugers Archiv European Journal of Physiology, 2008, 456, 349-358.	2.8	8
122	Do Î±₁â€adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?. Neurourology and Urodynamics, 2008, 27, 226-230.	1.5	61
123	Regulation of G protein-coupled receptor signalling: Focus on the cardiovascular system and regulator of G protein signalling proteins. European Journal of Pharmacology, 2008, 585, 278-291.	3.5	79
124	S1P receptor signalling and RGS proteins; expression and function in vascular smooth muscle cells and transfected CHO cells. European Journal of Pharmacology, 2008, 600, 1-9.	3.5	15
125	Cholinergic Innervation and Muscarinic Receptors in the Human Prostate. European Urology, 2008, 54, 326-334.	1.9	58
126	Physiological and pathological regulation of the autonomic control of urinary bladder contractility. , 2008, 117, 297-312.		79

#	Article	IF	Citations
127	Drug-Induced Urinary Incontinence. Drugs and Aging, 2008, 25, 541-549.	2.7	73
128	Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opinion on Pharmacotherapy, 2008, 9, 1787-1796.	1.8	105
129	Pharmacogenomics of G Protein-Coupled Receptor Ligands in Cardiovascular Medicine. Pharmacological Reviews, 2008, 60, 513-535.	16.0	33
130	Does Phospholipase C Mediate Muscarinic Receptor-Induced Rat Urinary Bladder Contraction?. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 998-1002.	2.5	30
131	Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 994-1005.	2.6	151
132	Epac and the cardiovascular system. Current Opinion in Pharmacology, 2007, 7, 193-200.	3.5	54
133	Vascular effects of sphingolipids. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 44-48.	1.5	33
134	Is the use of parasympathomimetics for treating an underactive urinary bladder evidenceâ€based?. BJU International, 2007, 99, 749-752.	2.5	140
135	Tools to study Î²3-adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 374, 385-398.	3.0	90
136	Validation of a rapid, non-radioactive method to quantify internalisation of G-protein coupled receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 375, 329-336.	3.0	10
137	Pitfalls in the normalization of real-time polymerase chain reaction data. Basic Research in Cardiology, 2007, 102, 195-197.	5.9	60
138	Tamsulosin â€“ modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia. Therapy: Open Access in Clinical Medicine, 2006, 3, 237-246.	0.2	8
139	Sequence of Echocardiographic Changes During Development of Right Ventricular Failure in Rat. Journal of the American Society of Echocardiography, 2006, 19, 1272-1279.	2.8	85
140	Effects of ??1-Adrenoceptor Antagonists on Male Sexual Function. Drugs, 2006, 66, 287-301.	10.9	119
141	Rho kinase: a target for treating urinary bladder dysfunction?. Trends in Pharmacological Sciences, 2006, 27, 492-497.	8.7	90
142	Sphingosine-1-phosphate and sphingosylphosphorylcholine: two of a kind?. British Journal of Pharmacology, 2006, 147, 347-348.	5.4	11
143	Î±₁â€‚Î±₂â€•and Î²â€‘adrenoceptors in the urinary bladder, urethra and prostate. British Journal of Pharmacology, 2006, 147, S88-119.	5.4	386
144	Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 37-44.	3.0	17

#	Article	IF	Citations
145	Effects of gender, age and hypertension on Î²-adrenergic receptor function in rat urinary bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 300-309.	3.0	56
146	How valid are animal models to evaluate treatments for pulmonary hypertension?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 391-400.	3.0	64
147	Comparison of three radioligands for the labelling of human Î²-adrenoceptor subtypes. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 99-105.	3.0	46
148	Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 79-85.	3.0	44
149	Tolerability of Amine Uptake Inhibitors in Urologic Diseases. Current Drug Safety, 2006, 1, 73-85.	0.6	15
150	Sphingosine Kinaseâ€“Dependent Activation of Endothelial Nitric Oxide Synthase by Angiotensin II. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2043-2048.	2.4	42
151	Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU International, 2005, 95, 19-28.	2.5	52
152	Role of muscarinic receptor antagonists in urgency and nocturia. BJU International, 2005, 96, 37-42.	2.5	36
153	Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder. European Urology, 2005, 48, 110-115.	1.9	43
154	Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 372, 71-78.	3.0	54
155	Duloxetine in the Treatment of Stress Urinary Incontinence. Women's Health, 2005, 1, 345-358.	1.5	17
156	Does Cyclic AMP Mediate Rat Urinary Bladder Relaxation by Isoproterenol?. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 260-267.	2.5	70
157	Multiple gene approaches to delineate the role of the renin-angiotensin-aldosterone system in nephropathy. Journal of Hypertension, 2005, 23, 269-272.	0.5	2
158	The Neuro-Urological Connection. European Urology Supplements, 2005, 4, 18-28.	0.1	28
159	A ROLE FOR MUSCARINIC RECEPTORS OR RHO-KINASE IN HYPERTENSION ASSOCIATED RAT BLADDER DYSFUNCTION?. Journal of Urology, 2005, 173, 2178-2181.	0.4	34
160	Novel muscarinic antagonists to treat incontinence and/or overactive bladder. Drug Discovery Today: Therapeutic Strategies, 2005, 2, 1-6.	0.5	13
161	Signal Transduction Underlying Carbachol-Induced Contraction of Rat Urinary Bladder. II. Protein Kinases. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 54-58.	2.5	48
162	Signal Transduction Underlying Carbachol-Induced Contraction of Human Urinary Bladder. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1148-1153.	2.5	152

#	Article	IF	Citations
163	Signal Transduction Underlying Carbachol-Induced Contraction of Rat Urinary Bladder. I. Phospholipases and Ca²⁺Sources. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 47-53.	2.5	76
164	Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. British Journal of Pharmacology, 2004, 143, 666-684.	5.4	134
165	Extracts from Rhois aromatica and Solidaginis virgaurea inhibit rat and human bladder contraction. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 281-286.	3.0	30
166	Small and intermediate conductance Ca 2+ -activated K + channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 602-615.	3.0	112
167	DOES CONCOMITANT STRESS INCONTINENCE ALTER THE EFFICACY OF TOLTERODINE IN PATIENTS WITH OVERACTIVE BLADDER?. Journal of Urology, 2004, 172, 601-604.	0.4	25
168	ASSOCIATION OF HYPERTENSION WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2004, 172, 1390-1393.	0.4	108
169	Safety of Telmisartan in Patients with Arterial Hypertension. Drug Safety, 2004, 27, 335-344.	3.2	53
170	Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3 receptors?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 524-531.	3.0	59
171	cAMP-independent relaxation of smooth muscle cells via G s -coupled receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 368, 329-330.	3.0	10
172	Comparison of signalling mechanisms involved in rat mesenteric microvessel contraction by noradrenaline and sphingosylphosphorylcholine. British Journal of Pharmacology, 2003, 138, 261-271.	5.4	21
173	Sphingosylphosphorylcholine, a naturally occurring lipid mediator, inhibits human platelet function. British Journal of Pharmacology, 2003, 138, 435-444.	5.4	12
174	p38 MAP kinase is a mediator of ischemic preconditioning in pigs. Cardiovascular Research, 2002, 55, 690-700.	3.8	74
175	A Benefit-Risk Assessment of Extended-Release Oxybutynin. Drug Safety, 2002, 25, 867-876.	3.2	29
176	Comparison of problem-and lecture-based pharmacology teaching. Trends in Pharmacological Sciences, 2002, 23, 168-170.	8.7	60
177	An Extract From the Bark of Aspidosperma Quebracho Blanco Binds to Human Penile Î±-Adrenoceptors. Journal of Urology, 2002, 168, 160-163.	0.4	16
178	Prevalence and Physician Awareness of Symptoms of Urinary Bladder Dysfunction. European Urology, 2002, 41, 234-239.	1.9	81
179	Problem- vs. lecture-based pharmacology teaching in a German medical school. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 366, 64-68.	3.0	19
180	Transient relaxation of rat mesenteric microvessels by ceramides. British Journal of Pharmacology, 2002, 135, 417-426.	5.4	18

#	Article	IF	Citations
181	M3 muscarinic receptors mediate contraction of human urinary bladder. British Journal of Pharmacology, 2002, 136, 641-644.	5.4	142
182	An extract from the bark of Aspidosperma quebracho blanco binds to human penile alpha-adrenoceptors. Journal of Urology, 2002, 168, 160-3.	0.4	5
183	Modulation of noradrenaline-induced microvascular constriction by protein kinase inhibitors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 57-65.	3.0	15
184	Mitogen-activated protein kinases in the heart. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 245-266.	3.0	109
185	In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic Î± 1A - vs. Î± 1B - and Î± 1D -adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 649-662.	3.0	28
186	Nifedipine inhibits sphingosine-1-phosphate-induced renovascular contraction in vitro and in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364, 179-182.	3.0	24
187	The prevention of migraine: a critical review with special emphasis on Î²-adrenoceptor blockers. British Journal of Clinical Pharmacology, 2001, 52, 237-243.	2.4	53
188	Do saw palmetto extracts block human?1-adrenoceptor subtypes in vivo?. Prostate, 2001, 46, 226-232.	2.3	23
189	Lysosphingolipid receptorâ€mediated diuresis and natriuresis in anaesthetized rats. British Journal of Pharmacology, 2001, 132, 1925-1933.	5.4	36
190	Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. British Journal of Pharmacology, 2000, 130, 1871-1877.	5.4	95
191	Sphingosineâ€1â€phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxinâ€sensitive manner. British Journal of Pharmacology, 2000, 130, 1878-1883.	5.4	77
192	Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1111-H1119.	3.2	66
193	Î±1-Adrenoceptor Subtypes Differentially Couple to Growth Promotion and Inhibition in Chinese Hamster Ovary Cells. Biochemical and Biophysical Research Communications, 2000, 272, 906-911.	2.1	48
194	EFFECT OF DIABETES ON LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2000, 163, 1725-1729.	0.4	154
195	Functional correlates of Î±2A-adrenoceptor gene polymorphism in the HANE study. Nephrology Dialysis Transplantation, 1999, 14, 2657-2663.	0.7	26
196	Myocardial Dysfunction in Donor Hearts. Circulation, 1999, 99, 2565-2570.	1.6	55
197	Saw palmetto extracts potently and noncompetitively inhibit human ?1-adrenoceptors in vitro. , 1999, 38, 208-215.		84
198	CHARACTERIZATION OF Î±-ADRENOCEPTOR SUBTYPES IN THE CORPUS CAVERNOSUM OF PATIENTS UNDERGOING SEX CHANGE SURGERY. Journal of Urology, 1999, 162, 1793-1799.	0.4	32

#	Article	IF	Citations
199	Differential Regulation of 46 and 54 kDa Jun N-Terminal Kinases and p38 Mitogen-Activated Protein Kinase by Human Î±1A-Adrenoceptors Expressed in Rat-1 Cells. Biochemical and Biophysical Research Communications, 1999, 261, 372-376.	2.1	10
200	CHARACTERIZATION OF ??-ADRENOCEPTOR SUBTYPES IN THE CORPUS CAVERNOSUM OF PATIENTS UNDERGOING SEX CHANGE SURGERY. Journal of Urology, 1999, , 1793.	0.4	4
201	Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation. Urological Research, 1998, 26, 149-154.	1.5	44
202	Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. British Journal of Clinical Pharmacology, 1998, 45, 49-55.	2.4	46
203	Differential Î±1-adrenoceptor labeling by []prazosin and []tamsulosin. European Journal of Pharmacology, 1998, 342, 85-92.	3.5	14
204	Stimulation of Î±1A-Adrenoceptors in Rat-1 Cells Inhibits Extracellular Signal-Regulated Kinase by Activating p38 Mitogen-Activated Protein Kinase. Molecular Pharmacology, 1998, 54, 755-760.	2.3	31
205	Tocolytic Therapy with Fenoterol Induces Selective Down-Regulation of Î²-Adrenergic Receptors in Human Myometrium¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1235-1242.	3.6	36
206	Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y. British Journal of Pharmacology, 1997, 120, 1335-1343.	5.4	49
207	Is Î±1D-adrenoreptor protein detactable in rat tissues?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 355, 438-446.	3.0	77
208	Prejunctional Neuropeptide Y Receptors in Human Kidney and Atrium. Journal of Cardiovascular Pharmacology, 1997, 29, 656-661.	1.9	28
209	Differential calcium signalling by m2 and m3 muscarinic acetylcholine receptors in a single cell type. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 352, 469-476.	3.0	32
210	[Pro34]peptide YY is a Y1-selective agonist at peptide YY/neuropeptide Y receptors. European Journal of Pharmacology, 1994, 269, 127-132.	2.6	11
211	Sensitization by dexamethasone of lymphocyte cyclic AMP formation: evidence for increased function of the adenylyl cyclase catalyst. British Journal of Pharmacology, 1994, 113, 240-246.	5.4	25
212	Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 347-352.	3.0	59
213	Is PP56 (D-myo-inositol-1, 2, 6-triphosphate) an antagonist at neuropeptide Y receptors?. Life Sciences, 1993, 52, 1835-1844.	4.3	17
214	Spare Receptors for Î²-Adrenoceptor-Mediated Positive Inotropic Effects of Catecholamines in the Human Heart. Journal of Cardiovascular Pharmacology, 1992, 19, 222-232.	1.9	81
215	Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a nonâ€peptide antagonist. British Journal of Pharmacology, 1992, 105, 71-76.	5.4	33
216	NPY and carbachol raise Ca2+ in SK-N-MC cells by three different mechanisms. Naunyn-Schmiedeberg's Archives of Pharmacology, 1992, 345, 370-4.	3.0	14

#	Article	IF	Citations
217	Receptors for neuropeptide Y: multiple subtypes and multiple second messengers. Trends in Pharmacological Sciences, 1991, 12, 389-394.	8.7	209
218	Does verapamil act as an immunomodulatory drug in vivo?. Immunopharmacology, 1991, 22, 85-91.	2.0	3
219	Renal Î±â€adrenergic receptor alterations: a cause of essential hypertension?. FASEB Journal, 1989, 3, 139-144.	0.5	44
220	Interaction Between Î±2-Adrenergic and NPY Receptor Pathways in Human Erythroleukemia Cells. Clinical and Experimental Hypertension, 1989, 11, 281-286.	0.3	3
221	Decreased myometrial Î²-adrenoceptors in women receiving Î²2-adrenergic tocolytic therapy: Correlation with lymphocyte Î²-adrenoceptors. Clinical Pharmacology and Therapeutics, 1989, 45, 1-8.	4.7	58
222	A new method for isolation of human lymphocyte subsets reveals differential regulation of Î²-adrenergic receptors by terbutaline treatment. Clinical Pharmacology and Therapeutics, 1989, 46, 429-439.	4.7	122
223	Elevation of plasma neuropeptide Y levels in congestive heart failure. American Journal of Medicine, 1989, 86, 43-48.	1.5	117
224	Myocardial beta-adrenoceptor changes in heart failure: concomitant reduction in beta,- and beta2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. Journal of the American College of Cardiology, 1989, 14, 323-331.	2.8	145
225	Molecular mechanism of Î²â€adrenergic receptor blockers with intrinsic sympathomimetic activity. FASEB Journal, 1988, 2, 2891-2894.	0.5	29
226	Arterial hypotension in chronic hemodialyzed patients. Kidney International, 1987, 32, 728-735.	5.2	69
227	Impact of the Neck and/or Shoulder Pain on Self-reported Headache Treatment Responses â€“ Results From a Pharmacy-Based Patient Survey. Frontiers in Neurology, 0, 13, .	2.4	4